Solta Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets energy-based medical device systems for aesthetic applications primarily in North America, the Asia Pacific, Europe, and the Middle East. It offers Fraxel re:pair system for use in dermatological procedures requiring ablation, coagulation, and resurfacing of soft tissue, as well as for rhytides, pigmentation, dyschromia, fine lines, acne, surgical scars, deeper lines, wrinkles, and actinic keratoses; and Clear + Brilliant system, a treatment to improve skin texture and help prevent the signs of aging skin. The company also provides Thermage CPT system that provides non-invasive treatment options...
25881 Industrial Boulevard
Hayward, CA 94545
Founded in 1996
Solta Medical, Inc. Announces Amendment and Restatement of Certificate of Incorporation
Jan 24 14
Solta Medical, Inc. amended and restated Certificate of Incorporation was amended and restated and the company's Amended and Restated Bylaws were amended and restated.
Solta Medical, Inc. Announces Management Changes
Jan 24 14
Pursuant to the terms of the Merger Agreement, on December 15, 2013, Solta Medical, Inc. entered into an Agreement and plan of merger with Valeant Pharmaceuticals International, Sapphire Subsidiary Corp. (the “Purchaser”), at the Effective Time, the directors and officers of the Purchaser immediately prior to the Effective Time became the directors and officers of Solta following the Effective Time. Accordingly, at the Effective Time, each of Mark M. Sieczkarek, Cathy L. McCarthy, David Holthe, Eric B. Stang, Harold Covert and Linda Graebner resigned as directors of Solta and any committee thereof. Each director resigned in accordance with the Merger Agreement, and no director resigned because of any disagreement with the Company on any matter relating to Solta’s operation, policies, or practices. Also at the Effective Time, Mr. Mark M. Sieczkarek, the Interim President and Chief Executive Officer, Mr. Jack Glenn, the Chief Financial Officer, Mr. H. Daniel Ferrari, Vice President of Finance, Mr. Doug W. Heigel, Vice President of Operations, Mr. Jeff Nardoci, Vice President of Worldwide Marketing, General Manager Surgical Specialties, and Dr. Lisa Parr, Vice President, Regulatory Affairs and Clinical Affairs, ceased being executive officers of Solta. At the Effective Time, Mr. J. Michael Pearson assumed the role of director, President and Chief Executive Officer of Solta, Mr. Howard B. Schiller assumed the role of director and Treasurer of Solta and Mr. Robert Chai-Onn assumed the role of director and Secretary of Solta. At the time Messrs. Schiller, Chai-Onn and Pearson assumed the roles of directors, it had not yet been determined on which committees, if any, of the Board of Directors of Solta Messrs. Schiller, Chai-Onn and Pearson would serve.
Solta Medical, Inc.(NasdaqGS:SLTM) dropped from NASDAQ Composite Index
Jan 23 14
Solta Medical, Inc. will be removed from the NASDAQ Composite Index.